Moreover, activation of the Met/TrkA-B pathway is involved in therapeutic resistance of GBM to CDK4/6 inhibitors, suggesting that dual inhibition of c-Met/Trk and CDK4/6 should be considered in resistant disease [30]. This evidence concerns the gene MET and glioblastoma.